AC5 Inhibitor for Obesity

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$133,845.00
Award Year:
2010
Program:
STTR
Phase:
Phase I
Contract:
1R41DK083826-01A1
Award Id:
n/a
Agency Tracking Number:
R41DK083826
Solicitation Year:
2010
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA09-081
Small Business Information
675 US Highway One, North Brunswick, NJ, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
145239112
Principal Investigator:
DOROTHYVATNER
(973) 972-1339
vatnerd@vasadebiosciences.com
Business Contact:
STEPHENVATNER
(973) 972-8920
vatner@vasadebiosciences.com
Research Institute:
Univ Of Med/ Dent Of Nj-Sch/Hlth Rel Pro

Health Related Professions
NEWARK, NJ, 07107-3001
() -

Abstract
DESCRIPTION (provided by applicant): The goal of this proposal is to develop a drug that will be therapeutic for obesity and diabetes and improve exercise tolerance. Obesity, diabetes and exercise are inextricably linked such that an agent that improves exercise tolerance or prevents obesity or the development of diabetes will likely have a therapeutic role in all three conditions. Obesity is a global epidemic, which promotes diabetes and is a major cardiovascular risk factor, resulting in reduced life expectancy. Obesity and diabetes can be caused by dietary, behavioral and genetic factors. Both diseases are a public health problem and finding a novel therapeutic approach would be a major advance. Recently, we reported a novel, genetically engineered mousemodel, where the adenylyl cyclase (AC) type 5 isoform is knocked out (AC5 KO). AC5 inactivation resulted in increased longevity and was protective against stress. Furthermore, the AC5 KO mice ate more than WT mice, but weighed less, suggesting that AC5 inhibition could be a novel approach to weight loss. The AC5 KO mouse also demonstrates enhanced exercise tolerance. Concurrently, we have developed a pharmacological AC5 inhibitor which also protects against cardiovascular stress. The main hypothesis of thispilot project is that inhibition of AC5 in mice protects against obesity. Our three working hypotheses are: A. Inhibition of AC5 will reduce obesity in mice fed a high fat diet, and B. Inhibition of AC5 will protect against the development of insulin resistance and diabetes, and C. Inhibition of AC5 will improve exercise tolerance in those mice. In view of the significance of obesity and diabetes in the US population, there is a major health benefit to this project. PUBLIC HEALTH RELEVANCE: Obesityis a global epidemic, which promotes diabetes and is a major cardiovascular risk factor, resulting in reduced life expectancy. Obesity and diabetes can be caused by dietary, behavioral and genetic factors; several genes have been identified to be involvedin the development of obesity. Both diseases are a public health problem and finding a novel therapeutic approach would be a major advance.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government